Lilly reported earlier this month that its revenue in the latest fiscal quarter jumped 45% with its new products contributing more than $3.1 billion, driven mainly by strong demand for Mounjaro ...

Eli Lilly's weight-loss drugs include Mounjaro and Zepbound.Sandy Huffaker for The Washington Post/Getty Images Weight-loss drugs such as Ozempic and Zepbound cost $900 to $1,500 for a month's supply.

“I had no idea this could happen,” he said, noting that he plans to file a lawsuit against Mounjaro drugmaker Lilly and Company. Sabellico pictured the first month he was on Ozempic. He lost ...

In February last year, CEO David Ricks told Reuters that Lilly expects to launch Mounjaro in India as early as 2025. Mounjaro, chemically known as tirzepatide, is currently sold in the UK and ...

Of course, Lilly's most important new products are diabetes treatment Mounjaro and weight management medicine Zepbound, which share the active ingredient tirzepatide. In 2024, Eli Lilly's revenue ...

The move follows a similar price reduction by competitor Eli Lilly for its weight-loss drug Mounjaro. Less than two weeks after Zepbound-maker Eli Lilly reduced the price of the weight-loss drug ...

In addition to Novo Nordisk (which provides Ozempic), Eli Lilly and its Mounjaro weight-loss drug have seen incredible growth over the course of the past year. This surge in growth has led LLY ...

Three of the new sites would produce active pharmaceutical ingredients for its drugs, and the fourth would produce sterile injectable medicines such as diabetes drug Mounjaro, Lilly said Wednesday.

including the popular weight-loss drug Mounjaro. Eli Lilly said the investment will create 3,000 high-skilled positions and approximately 10,000 construction jobs. Eli Lilly has unveiled plans to ...

David Ricks, the CEO of Mounjaro and Zepbound maker Eli Lilly, explained why these medications are so expensive on the "In Good Company with Nicolai Tangen" podcast this week. Developing a new ...